Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

Slides:

Advertisements

Similar presentations

18Feb2009VRBPAC Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Advertisements

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Influenza Vaccine Manufacturing

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

Preparation of Reference Influenza Viruses in Mammalian Cells: FDA Perspective Prepared for the Vaccines and Related Biological Products Advisory Committee.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Challenges of the 2009 H1N1 Pandemic Influenza: Charles Penn Global Influenza Programme World Health Organization Geneva.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

0 HHS Influenza Vaccine Projects for NVAC Meeting November 29-30, 2005 By: Dr. Robin Robinson Sr. Project Officer ORDC/OPHEP/DHHS.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

WHO PANDEMIC PHASES INTERPANDEMIC PERIOD Phase 1 Phase 2 PANDEMIC ALERT PERIOD Phase 3 Phase 4 Phase 5 PANDEMIC PERIOD Phase 6 POSTPANDEMIC PERIOD.

Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.

A Brief Update of Global Situation and Response to Pandemic Influenza A(H1N1) 2009 Wenqing Zhang MD Global Influenza Programme WHO HQ THE 3rd MEETING OF.

Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Vaccines for Children Program Stockpile Status National Vaccine Advisory Committee February 4, 2010 Washington, DC Lance E Rodewald, MD Director, Immunization.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.

Update on Pandemic Vaccine Development 3 rd WHO WPRO/SEARO NIC Meeting August, 2009, Beijing Masato Tashiro, MD., PhD. Director, WHO Collaborating.

Food and Drug Administration

Texas Immunization Branch Influenza Update July 24 th, 2008.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

The Current Season: A Review of the Influenza Season Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE USPHS INFLUENZA VIRUS VACCINE STRAIN SELECTION

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.

TM OPV Stockpiling in the United States Trudy V. Murphy, M.D. National Immunization Program Centers for Disease Control and Prevention February 5, 2003.

National Vaccine Advisory Committee Report from the Chair Gus Birkhead, MD, MPH NVAC Chair February 3, 2010.

A Vaccine Supply Update For The U.S. Market A Presentation At The National Vaccine Advisory Committee Meeting June 3, 2003 Dean Mason Chief, Program Support.

INFLUENZA UPDATE DEBBYE ROSEN ADULT IMMUNIZATION COORDINATOR CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.

Influenza Virus Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Update on Surveillance for Influenza Viruses with Pandemic Potential and Candidate Vaccine Viruses Nancy Cox, PhD CDC.

A Vaccine Supply Update For The U.S. Market A Presentation At National Advisory Committee Meeting February 4, 2003 Dean Mason Chief, Program Support Branch.

1 NVAC Washington, D.C. February 3, Agenda I.Overview of Influenza Vaccine Production and Development II.Vaccine Supply/Demand: Recent Trends.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

PROJECT MANAGEMENT Influenza Annual Update Weesp, February Dorine Leyssius.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

Update from the Office of Vaccines Research and Review, CBER/FDA NVAC Meeting Washington, D.C. February 4-5, 2003.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Options for Influenza Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological.

STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.

Regulatory Perspective on Trends in Veterinary Biologics Byron Rippke, DVM Nancy Clough, DVM, PhD Director, Center for Veterinary Biologics U.S. Department.

1 Influenza Vaccination 2016 Cluster: Communicable Disease, NDoH.

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

ACIP Recommendations Update for the U.S. Influenza Season

Recommended Timeline for Influenza Vaccinations

Planning for Pandemic Influenza

Presentation transcript:

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for presentation to VRBPAC Meeting 21 February 2008

Influenza Vaccine Manufacturing – Critical Factors Growth potential of seed virus –The quantity of trivalent influenza vaccine that can be produced is limited by the least productive monovalent strain Timing of strain selection –Available production time is limited due to necessity of distributing and administering vaccine prior to influenza season –Working seeds require at least 4 weeks (from receipt of seed candidate) for development prior to use in large-scale manufacturing Potency test reagents –Required to determine the potency of monovalent components prior to formulation of trivalent vaccine (SRID) –Must be produced/standardized for new strains Timing of Annual License Supplement Approval –Product release

Influenza Vaccine Manufacturing Model Timeline Jan Dec 2006Nov 2007 FebMarAprMayJunJulAugSepOct Manufacture Strain 1Manufacture Strain 2 Distribute VaccineStrain Balancing Produce & Standardize Potency Reagents Annual License Approval Formulate Bulk Trivalent Vaccine Fill & Package Manufacture Strain 3 Produce Working Seed Produce Reassortant

Current Manufacturing Status Production of monovalent strain(s) is underway –Production initiated “at risk of the strain(s) not being selected” for 2008 – 2009 Northern Hemisphere Influenza Vaccine to ensure sufficient vaccine supply. –Based on the publicly available surveillance information, manufacturers have chosen to produce the A/H1N1 A/Solomon Islands/3/2006 and/or B/Florida/4/2006-like strain(s) at-risk. –However WHO have not recommended A/Solomon Islands/3/2006 for the 2008 – 2009 season. –Three new strains for 2008 – 2009 Northern Hemisphere Influenza season is unprecedented for Northern Hemisphere in the last 20 years and will make it a very challenging year.

Evaluation of potential new strains H1N1 IVR 148 A/Brisbane/59/2007 received by most manufacturers only recently and is currently still under evaluation. Hy A/South Dakota/06/2007, NYMC X-173, X-173A, X-173B and X-173C shipped to manufacturers Monday & Tuesday this week. B strains Both B/Florida/4/06 and B/Brisbane/3/07 were used in production for the Southern Hemisphere. Other viruses recently provided by CDC/NIBSC - B/Bangladesh/3333/2007, B/Delaware/01/2007 and B/Pennsylvania/7/2007 do not appear to offer any yield advantage." H3N2 IVR 147 A/Brisbane/10/2007 is not a viable candidate for NH production due to low yield demonstrated during Southern Hemisphere production. X 171B A/Brisbane/10/2007 gives acceptable yield but has A198DEL –Additional serological studies taking place at CDC. A/Uruguay/716/2007 –CSL, NIBSC and NYMC all have promising reassortants in progress. »NYMC due to ship 25 & 26 February »CSL & NIBSC should be available latest - week commencing 3 March 2008

Public/Private Cooperation is necessary for successful Influenza Vaccine production & supply Timely Committee selection of the appropriate antigens –Consideration of antigenic match as well as growth potential Availability of seed viruses –Especially High Growth Reassortants –Opportunity for manufacturers to evaluate growth characteristics of potential strain candidates Availability of potency test reagents for all three strains by early June. Timely approval of Annual License Supplement

YearStrainChange 1989 FormulationA/Taiwan/1/86 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1990 FormulationA/Taiwan/1/86 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1991 FormulationA/Taiwan/1/86 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1992 FormulationA/Taiwan/1/86 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1993 FormulationA/Taiwan/1/86 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1994 FormulationA/Texas/36/91 (H1N1) [A/Singapore/6/86 (H1N1) - Like]X 1995 FormulationA/Texas/36/91 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1996 FormulationA/Texas/36/91 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1997 FormulationA/Texas/36/91 (H1N1) [A/Singapore/6/86 (H1N1) - Like] 1998 FormulationA/Beijing/262/95 X-127 (H1N1) [A/Beijing/262/95 (H1N1) - Like](Johannesburg NIB39)X 1999 FormulationA/Beijing/262/95 X-127 (H1N1) [A/Beijing/262/95 (H1N1) - Like](Johannesburg NIB39) 2000 FormulationA/New Caledonia/20/99 IVR-116 (H1N1) [A/New Caledonia/20/99 (H1N1) - Like]X 2001 FormulationA/New Caledonia/20/99 IVR-116 (H1N1) [A/New Caledonia/20/99 (H1N1) - Like] 2002 FormulationA/New Caledonia/20/99 IVR-116 (H1N1) [A/New Caledonia/20/99 (H1N1) - Like] 2003 FormulationA/New Caledonia/20/99 IVR-116 (H1N1) [A/New Caledonia/20/99 (H1N1) - Like] 2004 FormulationA/New Caledonia/20/99 IVR-116 (H1N1) [A/New Caledonia/20/99 (H1N1) - Like] 2005 FormulationA/New Caledonia/20/99 IVR-116 (H1N1) [A/New Caledonia/20/99 (H1N1) - Like] 2006 FormulationA/New Caledonia/20/99 IVR-116 (H1N1) [A/New Caledonia/20/99 (H1N1) - Like] 2007 FormulationA/Solomon Islands/3/2006 (H1N1)-like virusX 2008 FormulationA/Brisbane/59/2007 (H1N1)-like virusX 5 changes H1N1 NH strain changes since 1989

YearStrainChange 1989 FormulationA/OMS/5389/88 (WIC 160) (H3N2) [A/Shanghai/11/87 - Like] 1990 FormulationA/Shanghai/16/89 (NIB 24) (H3N2) [A/Guizhou/54/89 - Like]X 1991 FormulationA/Beijing/353/89 (H3N2)X 1992 FormulationA/Beijing/353/89 (H3N2) 1993 FormulationA/Beijing/353/89 (H3N2) 1994 FormulationA/Shangdong/9/93 (H3N2)X 1995 FormulationA/Johannesburg/33/94 (H3N2)X 1996 FormulationA/Nanchang/933/95 (H3N2) [A/Wuhan/359/95 (H3N2) - Like]X 1997 FormulationA/Nanchang/933/95 (H3N2) [A/Wuhan/359/95 (H3N2) - Like] 1998 FormulationA/Sydney/5/97 RESVIR -13 (H3N2) [A/Sydney/5/97 (H3N2) - Like]X 1999 FormulationA/Sydney/5/97 RESVIR -13 (H3N2) [A/Sydney/5/97 (H3N2) - Like] 2000 FormulationA/Sydney/5/97 RESVIR -13 (H3N2) [A/Sydney/5/97 (H3N2) - Like] 2001 FormulationA/Moscow/10/99 (H3N2) - Like (A/Panama/2007/99 RESVIR 17)X 2002 FormulationA/Moscow/10/99 (H3N2) - Like (A/Panama/2007/99 RESVIR 17) 2003 FormulationA/Moscow/10/99 (H3N2) - Like (A/Panama/2007/99 RESVIR 17) 2004 FormulationA/Fujian/411/2002-like (H3N2) [A/Wyoming/3/2003]X 2005 FormulationA/California/7/2004-like (H3N2) [A/New York/55/2004]X 2006 FormulationA/Wisconsin/67/2005 (H3N2)-likeX 2007 FormulationA/Wisconsin/67/2005 (H3N2)-like 2008 FormulationA/Brisbane/10/2007 (H3N2)-like virusX 11 changes H3N2 NH strain changes since 1989

B strain NH changes since 1989 YearSreainChange 1989 FormulationB/Yamagata/16/ FormulationB/Yamagata/16/ FormulationB/Yamagata/16/ FormulationB/Yamagata/16/ FormulationB/Panama/45/90X 1994 FormulationB/Panama/45/ FormulationB/Harbin/7/94 [B/Beijing/184/93 - Like]X 1996 FormulationB/Harbin/7/94 [B/Beijing/184/93 - Like] 1997 FormulationB/Harbin/7/94 [B/Beijing/184/93 - Like] 1998 FormulationB/Harbin/7/94 [B/Beijing/184/93 - Like] 1999 FormulationB/Yamanashi/166/98 [B/Beijing/184/93 - Like]X 2000 FormulationB/Yamanashi/166/98 [B/Beijing/184/93 - Like] 2001 FormulationB/Sichuan/379/99 - Like (B/Guangdong/120/00)X 2002 FormulationB/Hong Kong/330/01X 2003 FormulationB/Hong Kong/330/ FormulationB/Shanghai/361/2002-like [B/Jiangsu/10/2003]X 2005 FormulationB/Shanghai/361/2002-like [B/Jiangsu/10/2003] 2006 FormulationB/Malaysia/2506/2004X 2007 FormulationB/Malaysia/2506/ FormulationB/Florida/4/2006-like virusX 8 changes

Summary Years covered20 H1N1 changes5 H1N1 change rate (yrs between changes)4.00 H3N2 changes11 H3N2 change rate (yrs between changes)1.82 B changes8 B change rate (yrs between changes)2.50 Zero strain changes in a single year4 times 1 strain change in a single year9 times 2 strain changes in a single year6 times 3 strain changes in a single year1 ( ?) Summary - NH strain changes since 1989